Clinical Trial Update: HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update reports the termination of the Phase 1/2 study evaluating HB-302/HB-301 therapy in metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• HB-301
• HB-302

Snippet

Sponsor: Hookipa Biotech GmbH | Conditions: Prostate Cancer Metastatic | Phase 1, Phase 2 | Status: TERMINATED